Tech Company Financing Transactions
enGene Funding Round
enGene closed a $13.3 million funding round on 8/6/2013. Backers included Lumira Capital and private investors.
Transaction Overview
Company Name
Announced On
8/6/2013
Transaction Type
Venture Equity
Amount
$13,250,000
Round
Undisclosed
Investors
Lumira Capital (Lead Investor) (Brian Underdown)
Proceeds Purpose
This financing is targeted to provide the resources to ensure that we can advance the development of ourplatform technology to achieve several key value-defining milestones.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7171 Frederick-Banting
Montreal QC, H4S 1Z9
Canada
Montreal QC, H4S 1Z9
Canada
Phone
Website
Email Address
Overview
enGene is a biotechnology company developing a mucosal immunotherapy platform for the treatment of inflammatory bowel disease and diabetes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Richard Glickman
Chief Executive Officer
Jason Hanson
Chief Scientific Officer
José Lora
Chief Technical Officer
Anthony Cheung
Browse more venture capital transactions:
Prev: 8/6/2013: MoJiva venture capital transaction
Next: 8/6/2013: Tegile Systems venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs